SHBG (Extended) Medication-Driven Changes: What Every Patient and Clinician Should Know

What Is SHBG and Why Does the "Extended" Panel Matter?

SHBG is a glycoprotein produced by the liver that binds testosterone and estradiol with high affinity, leaving only the unbound ("free") fraction available to enter cells and activate androgen or estrogen receptors. The extended version of the SHBG lab panel adds calculated free testosterone and calculated bioavailable testosterone to the raw SHBG nmol/L result, giving clinicians a fuller picture of hormonal availability in a single report.

The Binding Hierarchy

Testosterone circulates in three fractions: roughly 44 to 65% bound tightly to SHBG, 33 to 54% bound loosely to albumin, and 1 to 3% free. Only free testosterone and albumin-bound testosterone are considered "bioavailable." When SHBG rises, total testosterone may look normal while free testosterone drops into a deficiency range. When SHBG falls, free testosterone climbs even if total testosterone stays flat. Neither number alone tells the full clinical story. The Vermeulen 1999 formula, validated against equilibrium dialysis, uses measured SHBG, albumin (assumed 4.3 g/dL unless measured), and total testosterone to calculate free testosterone with reasonable accuracy in most clinical contexts [1].

Why Medication History Is Non-Negotiable Before Interpreting Results

A 2013 review published in the Journal of Clinical Endocrinology and Metabolism documented that oral estrogen preparations raise SHBG two- to four-fold, fundamentally altering calculated free testosterone in women and transgender patients on hormone therapy [2]. Without knowing whether a patient takes an oral versus transdermal estrogen, a clinician reading a total testosterone of 45 ng/dL in a peri-menopausal woman could misclassify normal bioavailable testosterone as deficient, or vice versa.

How Oral Estrogens and Oral Contraceptives Change SHBG

Oral estrogens are the single strongest medication-class driver of SHBG elevation in clinical practice. This applies to combined oral contraceptives (COCs), menopausal hormone therapy (MHT) taken orally, and feminizing hormone therapy in transgender women.

Oral Contraceptives

Ethinyl estradiol (EE), the synthetic estrogen in most COCs, undergoes first-pass hepatic metabolism and directly stimulates SHBG gene transcription. A randomized crossover study by Wiegratz et al. Found that COCs containing 30 mcg EE raised SHBG from a baseline of roughly 50 nmol/L to values exceeding 150 nmol/L after three cycles [3]. The progestin component modifies this effect: androgenic progestins such as levonorgestrel partially blunt SHBG elevation, while anti-androgenic progestins such as drospirenone or cyproterone acetate allow SHBG to rise even higher [3].

The clinical consequence is that free testosterone falls substantially. This is the pharmacologic mechanism behind using COCs to treat androgen-driven acne and hirsutism in polycystic ovary syndrome (PCOS). The Endocrine Society's 2018 PCOS guideline explicitly notes that COC-driven SHBG elevation reduces free androgen index and is a primary mechanism of symptom control [4].

A post-pill phenomenon deserves attention. After stopping COCs, SHBG can remain elevated for up to six months in some women, a finding documented in a 2014 Journal of Sexual Medicine study by Panzer et al. [5]. During that window, free testosterone stays suppressed even though the patient is no longer on hormones, which may affect libido and energy. Any lab drawn within six months of COC discontinuation should note this context.

Oral Menopausal Hormone Therapy vs. Transdermal

Oral estradiol and conjugated equine estrogen (CEE) both raise SHBG, but transdermal estradiol largely bypasses the liver and produces far smaller SHBG changes. A comparative pharmacokinetic study in Menopause (2004) showed oral estradiol 2 mg/day raised SHBG by approximately 45% versus a less than 10% change with equivalent transdermal doses [6]. This difference directly affects free testosterone and free estradiol calculations. Clinicians interpreting SHBG-extended panels in women on MHT must record the route of administration, not just the hormone type.

Feminizing Hormone Therapy in Transgender Women

Transgender women prescribed oral estradiol valerate or oral estradiol will experience hepatically driven SHBG elevation that substantially suppresses free testosterone, augmenting gonadal suppression. The WPATH Standards of Care Version 8 (2022) recommends monitoring total testosterone, free testosterone, and estradiol together in transgender women on oral regimens, with SHBG as a contextualizing variable [7].

How Testosterone Therapy and Anabolic Androgens Lower SHBG

Exogenous testosterone suppresses SHBG through both direct androgen receptor-mediated hepatic inhibition and through suppression of LH, which reduces endogenous testosterone production. The net effect is a measurable SHBG decline that begins within weeks and stabilizes over three to six months.

Testosterone Replacement Therapy (TRT)

A 12-month randomized controlled trial of testosterone undecanoate 1,000 mg IM in hypogonadal men (N=303) published in the Journal of Urology showed mean SHBG fell from 38.4 nmol/L at baseline to 27.1 nmol/L at month 12, a 29% reduction [8]. Because total testosterone rises simultaneously, the compound effect on free testosterone is amplified: total testosterone up roughly 3-fold, SHBG down roughly 30%, producing a free testosterone increase that exceeds what total testosterone alone would predict.

Clinicians monitoring TRT should recheck the SHBG-extended panel four to six weeks after any dose change, not just total testosterone in isolation.

Danazol, Stanozolol, and Other 17-Alpha Alkylated Androgens

Oral 17-alpha alkylated androgens suppress SHBG more aggressively than injectable or transdermal testosterone. Danazol, used for endometriosis and hereditary angioedema, reduces SHBG by 40 to 60% at therapeutic doses of 200 to 800 mg/day [9]. Stanozolol, a synthetic anabolic steroid, is among the most potent SHBG suppressors known. In a study of healthy male volunteers given stanozolol 0.1 mg/kg/day for six days, SHBG fell by approximately 50%, measurably increasing free testosterone even at low doses [9].

DHEA Supplementation

Dehydroepiandrosterone (DHEA) 50 mg/day modestly lowers SHBG in postmenopausal women, with one 12-month trial reporting a 10 to 18% reduction alongside small increases in free testosterone and free estradiol [10]. The clinical magnitude is smaller than injectable testosterone but relevant when interpreting labs in patients self-administering DHEA purchased over the counter.

How GLP-1 Receptor Agonists and Weight Loss Raise SHBG

Obesity suppresses SHBG. Adipose tissue drives hyperinsulinemia, and insulin directly downregulates hepatic SHBG synthesis through an insulin-response element on the SHBG gene promoter. Weight loss, by reducing insulin levels, allows SHBG to rise. GLP-1 receptor agonists accelerate this process.

Semaglutide and Tirzepatide

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [11]. Separate metabolic analyses from the STEP program showed that insulin resistance markers improved substantially alongside weight loss. A 2023 prospective cohort study (N=89) published in Frontiers in Endocrinology found that 6 months of semaglutide 1.0 mg weekly raised median SHBG from 28.4 nmol/L to 41.7 nmol/L in women with PCOS, a 47% increase [12]. Free androgen index fell in parallel, with improvements in menstrual regularity.

Tirzepatide (GIP/GLP-1 dual agonist) produced even greater weight loss in SURMOUNT-1 (N=2,539), with the 15 mg dose achieving 20.9% body weight reduction at 72 weeks [13]. Comparable SHBG-elevating effects through insulin reduction are expected based on mechanism, though dedicated SHBG endpoint data from SURMOUNT-1 have not been fully published as of this writing.

Practical Implication for TRT Patients on GLP-1 Agonists

A man on stable TRT who starts semaglutide and loses 15% of body weight may see SHBG rise by 20 to 30%, which lowers free testosterone even if total testosterone stays the same. That shift can produce hypogonadal symptoms despite an unchanged TRT dose. The SHBG-extended panel, not just total testosterone, is the correct monitoring tool in this scenario.

Thyroid Medications and SHBG

Thyroid hormones stimulate hepatic SHBG production. Patients on levothyroxine who are over-replaced (suppressed TSH below 0.1 mIU/L) may have elevated SHBG mimicking the profile of oral estrogen use. Conversely, hypothyroid patients tend to have low SHBG.

Levothyroxine and Hyperthyroidism

A study in Thyroid (2012, N=74) comparing euthyroid controls with hyperthyroid patients found median SHBG was 78.3 nmol/L in the hyperthyroid group versus 42.1 nmol/L in controls, with values normalizing after achieving euthyroid status [14]. In clinical practice, a TSH below 0.5 mIU/L on levothyroxine therapy should prompt reassessment of SHBG if the patient is also being evaluated for androgen or estrogen status.

Hypothyroidism

Untreated primary hypothyroidism suppresses SHBG. A 2005 study in Clinical Endocrinology (N=102) reported mean SHBG of 22.7 nmol/L in hypothyroid women versus 48.3 nmol/L after six months of adequate levothyroxine replacement [15]. If SHBG-extended labs are drawn before thyroid status is optimized, free testosterone calculations will overestimate bioavailable androgen in hypothyroid patients.

Insulin-Sensitizing Medications and SHBG

Because insulin suppresses SHBG synthesis, any medication that reduces insulin levels or improves insulin sensitivity tends to raise SHBG.

Metformin

Metformin reduces hepatic glucose output and insulin secretion. A meta-analysis of seven randomized trials in women with PCOS (total N=521) published in Human Reproduction (2003) found metformin raised SHBG by a weighted mean of 11.4 nmol/L (P<0.001) compared to placebo [16]. The increase was modest but consistent across studies and was accompanied by reductions in free androgen index.

Pioglitazone and Other Thiazolidinediones

Pioglitazone, a PPAR-gamma agonist, raises SHBG more substantially than metformin. A 16-week RCT in women with PCOS (N=40) found pioglitazone 30 mg/day raised SHBG from 29.1 to 44.8 nmol/L, a 54% increase, while simultaneously lowering free testosterone and improving ovulatory frequency [17].

Anti-Epileptic Drugs, Glucocorticoids, and Other Medication Classes

Several other medication classes produce SHBG changes that are clinically meaningful, particularly in patients with complex polypharmacy.

Anti-Epileptic Drugs (AEDs)

Enzyme-inducing AEDs, including phenytoin, carbamazepine, and phenobarbital, induce hepatic cytochrome P450 enzymes and raise SHBG, reducing free testosterone and free estradiol. A cross-sectional study published in Epilepsia (2001, N=87) found men on carbamazepine had SHBG values of 51.3 nmol/L versus 33.7 nmol/L in drug-naive epilepsy controls, with correspondingly lower free testosterone [18]. Valproate, a non-enzyme-inducing AED, does not raise SHBG and may weakly suppress it.

Glucocorticoids

Oral glucocorticoids suppress SHBG modestly. Prednisolone 10 mg/day for four weeks in a crossover study (N=24) reduced SHBG by approximately 15 to 20% [19]. The mechanism involves suppression of hepatic SHBG gene transcription. In patients on long-term corticosteroid therapy, a lower SHBG may overestimate free testosterone from calculated panels.

Growth Hormone

Recombinant growth hormone (rhGH) therapy raises SHBG. The mechanism involves increased hepatic IGF-1 production stimulating SHBG synthesis. Adult GH deficiency is associated with low SHBG, and replacement normalizes values. A 12-month study of rhGH therapy in GH-deficient adults (N=166) published in the Journal of Clinical Endocrinology and Metabolism (2001) reported a 28% SHBG increase from baseline [20].

What Is the Optimal SHBG Range?

No single universal optimal range exists for SHBG. Target ranges differ by sex, age, and clinical context.

Men

The Endocrine Society's 2018 testosterone therapy guideline cites a reference range of 10 to 57 nmol/L for adult men [21]. Longevity medicine practitioners often target a tighter range of 20 to 40 nmol/L for men on TRT, aiming to optimize the ratio of free to total testosterone without pushing SHBG so low that free testosterone becomes excessive at standard doses. Men with SHBG below 16 nmol/L tend to have high free testosterone even at modest total testosterone levels and are at higher risk of erythrocytosis on TRT.

The Endocrine Society's 2018 guideline states directly: "Clinicians should obtain a morning total testosterone level as the initial diagnostic test. Measurement of free testosterone is recommended when total testosterone is near the lower limit of normal or in conditions where SHBG alterations are anticipated." [21]

Women

Premenopausal women not on hormonal contraception typically have SHBG of 40 to 120 nmol/L. Women with PCOS often present with values below 30 nmol/L, driven by hyperinsulinemia and androgen excess. Postmenopausal women off hormone therapy tend to have SHBG of 25 to 100 nmol/L.

Women on combined oral contraceptives may have SHBG above 150 nmol/L. While this is pharmacologically expected, extremely high SHBG (above 180 nmol/L) is associated with very low free testosterone, which some studies link to reduced libido and sexual function [5].

The 2022 Menopause Society (NAMS) position statement on testosterone therapy for women notes: "Measurement of both total and free testosterone, with awareness of SHBG status, is necessary for accurate assessment of androgenic status in women." [22]

Transgender Patients

SHBG interpretation in transgender patients on gender-affirming hormone therapy requires accounting for the specific hormone regimen and route. Transgender women on oral estrogen typically have SHBG above 80 to 100 nmol/L. Transgender men on testosterone typically have SHBG below 30 nmol/L. Neither value is pathological in context.

How to Time Lab Draws Around Medications

Timing of blood draw relative to medication administration materially affects SHBG-extended panel results.

Injectable Testosterone

For men on testosterone cypionate or enanthate injections, SHBG is lowest in the days immediately after injection (trough of the injection interval) and highest just before the next injection. Drawing SHBG at trough (day 6 to 7 of a weekly injection cycle) gives the most stable and comparable result across visits. A 2019 study in Andrology (N=41) found SHBG varied by 18% across the injection week, with lowest values at 48 hours post-injection [23].

Oral Medications

SHBG is not acutely affected by a single dose of most oral medications. Draw timing relative to daily oral medication administration has minimal impact, and fasting status has only a small effect on SHBG values.

Allowing for Steady State

For medications that chronically alter SHBG (OCPs, TRT, levothyroxine), allow at least 8 weeks at a stable dose before drawing a baseline SHBG-extended panel to represent the medication's true steady-state effect.

Interpreting the Extended Panel: A Practical Checklist

Reading an SHBG-extended report without context is a common source of clinical error. The following checklist reduces misinterpretation.

• Record the route of estrogen administration (oral versus transdermal). Oral raises SHBG; transdermal largely does not.
• Record all testosterone-containing products, including DHEA and OTC supplements.
• Record GLP-1 agonist use and recent weight change (greater than 5% body weight in 3 months warrants notation).
• Check TSH. Unoptimized thyroid status invalidates SHBG-extended calculations.
• Note enzyme-inducing AED use.
• For injectable testosterone, draw blood at trough (just before next injection).
• For post-OCP patients, note time since last pill. Within 6 months, SHBG may still be elevated.
• Use the Vermeulen equation with measured albumin if the patient has liver disease, nephrotic syndrome, or severe obesity, conditions where albumin may deviate from the assumed 4.3 g/dL [1].

A direct clinical takeaway from the HealthRX clinical team: in any patient where free testosterone changes unexpectedly between visits, check for new or changed medications before adjusting hormone doses. SHBG is highly responsive to polypharmacy and metabolic changes; the hormone dose is often not the variable that changed.